Gynecology

Gynecological applications of PRP address tissue regeneration in the vaginal mucosa, vulvar epithelium, and clitoral complex — tissues that undergo progressive atrophy with declining estrogen levels, chronic inflammatory conditions, and surgical changes. A 2025 scoping review of 43 studies confirmed that PRP improved symptoms and quality of life for vulvar lichen sclerosus, vulvovaginal atrophy, and sexual dysfunction.

The biological rationale is tissue-specific. Vulvovaginal atrophy involves thinning of the vaginal epithelium, loss of collagen and elastin, decreased vascularity, and reduced lubrication — all processes where PRP’s growth factors (EGF for epithelial proliferation, VEGF for angiogenesis, PDGF for fibroblast activation) have established mechanisms of action. Lichen sclerosus adds a chronic inflammatory component where the anti-inflammatory properties of protein-enriched PRP may provide additional benefit.

autologIX’s protein enrichment adds concentrated fibronectin for epithelial adhesion and migration, concentrated A2M for anti-inflammatory protease inhibition relevant to lichen sclerosus, and HGF for its documented anti-fibrotic and epithelial proliferative properties. The characterized exosome fraction carries anti-inflammatory miRNAs (including miR-146a, a known inhibitor of NF-kB inflammatory signaling). The 6–7 mL output volume accommodates treatment protocols involving multiple injection sites across the vaginal wall, introitus, and clitoral complex.

Clinical studies investigating autologIX outcomes for gynecological applications are in development.